๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Tobramycin dosage recommendation in patients with cystic fibrosis

โœ Scribed by R. L. Davis; P. Mendelman; Bonnie Ramsey; A. L. Smith

Publisher
Springer-Verlag
Year
1989
Tongue
English
Weight
188 KB
Volume
17
Category
Article
ISSN
0300-8126

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Reduced mortality in cystic fibrosis pat
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
โœ Gregory S. Sawicki; James E. Signorovitch; Jie Zhang; Dominick Latremouille-Viau ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 110 KB

## Abstract ## Background Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been wellโ€described. This study aimed to assess the association between use of

Falsely elevated serum tobramycin concen
Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin
โœ Okan Elidemir; Stephanie R. Maciejewski; Christopher M. Oermann ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 24 KB ๐Ÿ‘ 1 views

A recently developed tobramycin preparation for inhalation (TOBIเฎพ, Pathogenesis Corp., Seattle, WA) is widely used in CF patients. It is often used in conjunction with intravenous tobramycin. Renal and ototoxicity associated with the use of tobramycin require that serum drug concentrations be monito

Inhaled tobramycin and bronchial hyperac
Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis
โœ Maya Ramagopal; Larry C. Lands ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 60 KB

The use of inhaled tobramycin for prophylaxis and treatment of respiratory symptoms in cystic fibrosis (CF) is now widespread. There have been concerns that inhaling the intravenous (I.V.) formulation of tobramycin causes bronchoconstriction. Previous studies using this formulation have either not s

Evaluation of long term tobramycin thera
Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease
โœ U. Paporisz; H. G. Posselt; R. Wรถnne; W. Ristow; D. Rรถser; H. Knothe; S. W. Bend ๐Ÿ“‚ Article ๐Ÿ“… 1979 ๐Ÿ› Springer ๐ŸŒ English โš– 493 KB

To nine cystic fibrosis patients with chronic bronchopulmonary infection of severely damaged lungs invaded by Pseudomonas aeruginosa, eleven courses of prolonged tobramycin treatment (5 mg/kg/day) for four to 16 weeks were administered. Pulmonary symptoms improved and a better quality of life was ac